In this regard, evidence has been provided that a mutated p53 form can sustain Nrf2-mediated antioxidant response to allow cancer cell adaptation to the tumour-typical increased ROS levels [35] and to confer chemoresistance [36]. This evidence concerns the gene NFE2L2 and cancer.